Annotation Detail
Information
- Associated Genes
- IDH1
- Associated Variants
-
IDH1 MUTATION
IDH1 MUTATION - Associated Disease
- cholangiocarcinoma
- Source Database
- CIViC Evidence
- Description
- In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 months, and median overall survival was 13.8 months.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7447
- Gene URL
- https://civic.genome.wustl.edu/links/genes/26
- Variant URL
- https://civic.genome.wustl.edu/links/variants/645
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cholangiocarcinoma
- Evidence Direction
- Supports
- Drug
- Ivosidenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 31300360
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ivosidenib | Sensitivity | true |